MedTrace Logo

Uncomplicated Pelvic Inflammatory Disease. Treatment With Moxifloxacin.

NCT00683865 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 749

Last updated 2014-10-15

No results posted yet for this study

Summary

Comparison of various antibiotics in treatment of uncomplicated pelvic inflammatory disease

Conditions

  • Pelvic Inflammatory Disease

Interventions

DRUG

Ofloxacin

Ofloxacin 400 mg po bid plus metronidazole 500 mg po bid for 14 days

DRUG

Avelox (Moxifloxacin, BAY12-8039)

Moxifloxacin 400 mg po od for 14 days

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-04-30
Primary Completion
2004-10-31
Completion
2004-10-31

Countries

  • Denmark
  • Finland
  • France
  • Germany
  • Greece
  • Hungary
  • Italy
  • Lithuania
  • Poland
  • Russia
  • South Africa
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00683865 on ClinicalTrials.gov